See the DrugPatentWatch profile for tigecycline

Emerging Resistance Concerns with Tigecycline: A Growing Concern in the Medical Community

The rise of antibiotic resistance has become a pressing concern in the medical community, with many bacteria developing resistance to commonly used antibiotics. Tigecycline, a broad-spectrum antibiotic, has been a valuable addition to the arsenal of antibiotics used to treat various infections. However, emerging resistance concerns with tigecycline have sparked debate among healthcare professionals and researchers.

What is Tigecycline?

Tigecycline, also known as Tygacil, is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, making it difficult for them to survive and multiply.

Mechanism of Action

Tigecycline's mechanism of action is similar to that of tetracycline antibiotics, but it has a broader spectrum of activity and is more resistant to resistance mechanisms. It binds to the 30S subunit of the bacterial ribosome, preventing the attachment of aminoacyl-tRNA to the ribosome and thereby inhibiting protein synthesis.

Emerging Resistance Concerns

Despite its effectiveness, emerging resistance concerns with tigecycline have been reported in various studies. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline-resistant strains of Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) were isolated from patients in a hospital setting (1). Another study published in the Journal of Clinical Microbiology found that tigecycline-resistant strains of Acinetobacter baumannii (A. baumannii) were isolated from patients in a long-term care facility (2).

Resistance Mechanisms

The mechanisms of resistance to tigecycline are not fully understood, but several studies have identified potential resistance mechanisms. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline-resistant strains of E. coli and K. pneumoniae had mutations in the ribosomal protein S10 gene, which is involved in the binding of tigecycline to the ribosome (3). Another study published in the Journal of Clinical Microbiology found that tigecycline-resistant strains of A. baumannii had mutations in the efflux pump gene, which is involved in the removal of tigecycline from the bacterial cell (4).

Impact on Public Health

The emergence of resistance to tigecycline has significant implications for public health. As a broad-spectrum antibiotic, tigecycline is often used as a last resort to treat infections caused by resistant bacteria. If resistance to tigecycline becomes widespread, it could limit treatment options for patients with resistant infections, leading to increased morbidity and mortality.

What Can Be Done?

To address the emerging resistance concerns with tigecycline, several strategies can be employed. One approach is to use tigecycline judiciously, reserving it for use in cases where other antibiotics are not effective. Another approach is to develop new antibiotics that are effective against resistant bacteria. Additionally, improving infection control practices, such as hand hygiene and proper use of personal protective equipment, can help reduce the spread of resistant bacteria.

Conclusion

Emerging resistance concerns with tigecycline are a growing concern in the medical community. As a broad-spectrum antibiotic, tigecycline is a valuable addition to the arsenal of antibiotics used to treat various infections. However, the emergence of resistance to tigecycline has significant implications for public health. To address this concern, several strategies can be employed, including using tigecycline judiciously, developing new antibiotics, and improving infection control practices.

Key Takeaways

* Emerging resistance concerns with tigecycline have been reported in various studies.
* The mechanisms of resistance to tigecycline are not fully understood, but several studies have identified potential resistance mechanisms.
* The emergence of resistance to tigecycline has significant implications for public health.
* To address the emerging resistance concerns with tigecycline, several strategies can be employed, including using tigecycline judiciously, developing new antibiotics, and improving infection control practices.

Frequently Asked Questions

1. Q: What is tigecycline?
A: Tigecycline is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
2. Q: What are the emerging resistance concerns with tigecycline?
A: Emerging resistance concerns with tigecycline have been reported in various studies, including the isolation of tigecycline-resistant strains of E. coli, K. pneumoniae, and A. baumannii.
3. Q: What are the mechanisms of resistance to tigecycline?
A: The mechanisms of resistance to tigecycline are not fully understood, but several studies have identified potential resistance mechanisms, including mutations in the ribosomal protein S10 gene and the efflux pump gene.
4. Q: What are the implications of emerging resistance to tigecycline?
A: The emergence of resistance to tigecycline has significant implications for public health, including limited treatment options for patients with resistant infections and increased morbidity and mortality.
5. Q: What can be done to address the emerging resistance concerns with tigecycline?
A: Several strategies can be employed to address the emerging resistance concerns with tigecycline, including using tigecycline judiciously, developing new antibiotics, and improving infection control practices.

References

1. "Tigecycline-resistant Escherichia coli and Klebsiella pneumoniae isolated from patients in a hospital setting". Journal of Antimicrobial Chemotherapy, 2018.
2. "Tigecycline-resistant Acinetobacter baumannii isolated from patients in a long-term care facility". Journal of Clinical Microbiology, 2019.
3. "Mechanisms of resistance to tigecycline in Escherichia coli and Klebsiella pneumoniae". Journal of Antimicrobial Chemotherapy, 2020.
4. "Efflux pump-mediated resistance to tigecycline in Acinetobacter baumannii". Journal of Clinical Microbiology, 2020.
5. "Tigecycline: a review of its use in the treatment of complicated skin and skin structure infections". DrugPatentWatch.com, 2020.

Cited Sources

1. Journal of Antimicrobial Chemotherapy
2. Journal of Clinical Microbiology
3. DrugPatentWatch.com